27660323|t|Safety and efficacy of tranexamic acid in bleeding paediatric trauma patients: a systematic review protocol
27660323|a|Trauma is the leading cause of death among children aged 1-18. Studies indicate that better control of bleeding could potentially prevent 10-20% of trauma -related deaths. The antifibrinolytic agent tranexamic acid (TxA) has shown promise in haemorrhage control in adult trauma patients. However, information on the potential benefits of TxA in children remains sparse. This review proposes to evaluate the current uses, benefits and adverse effects of TxA in the bleeding paediatric trauma population. A structured search of bibliographic databases (eg, MEDLINE, EMBASE, PubMed, CINAHL, Cochrane CENTRAL) has been undertaken to retrieve randomised controlled trials and cohort studies that describe the use of TxA in paediatric trauma patients. To ensure that all relevant data were captured, the search did not contain any restrictions on language or publication time. After deduplication, citations will be screened independently by 2 authors, and selected for inclusion based on prespecified criteria. Data extraction and risk of bias assessment will be performed independently and in duplicate. Meta-analytic methods will be employed wherever appropriate. This study will not involve primary data collection, and formal ethical approval will therefore not be required. The findings of this study will be disseminated through a peer-reviewed publication and at relevant conference meetings. CRD42016038023.
27660323	0	6	Safety	T068	C0036043
27660323	11	19	efficacy	T080	C1280519
27660323	23	38	tranexamic acid	T109,T121	C0040613
27660323	42	50	bleeding	T046	C0019080
27660323	51	68	paediatric trauma	T037	C3714660
27660323	69	77	patients	T101	C0030705
27660323	81	98	systematic review	T170	C1955832
27660323	99	107	protocol	T170	C0442711
27660323	108	114	Trauma	T037	C3714660
27660323	130	135	cause	T169	C0015127
27660323	139	144	death	T033	C1306577
27660323	151	159	children	T100	C0008059
27660323	200	207	control	T080	C0243148
27660323	211	219	bleeding	T046	C0019080
27660323	238	245	prevent	T080	C2700409
27660323	256	262	trauma	T037	C3714660
27660323	272	278	deaths	T033	C1306577
27660323	284	306	antifibrinolytic agent	T121	C0003304
27660323	307	322	tranexamic acid	T109,T121	C0040613
27660323	324	327	TxA	T109,T121	C0040613
27660323	350	361	haemorrhage	T046	C0019080
27660323	362	369	control	T080	C0243148
27660323	373	378	adult	T100	C0001675
27660323	379	385	trauma	T037	C3714660
27660323	386	394	patients	T101	C0030705
27660323	434	442	benefits	T081	C0086387
27660323	446	449	TxA	T109,T121	C0040613
27660323	453	461	children	T100	C0008059
27660323	483	489	review	T170	C0282443
27660323	523	527	uses	T169	C0457083
27660323	529	537	benefits	T081	C0086387
27660323	542	557	adverse effects	T046	C0879626
27660323	561	564	TxA	T109,T121	C0040613
27660323	572	580	bleeding	T046	C0019080
27660323	581	598	paediatric trauma	T037	C3714660
27660323	599	609	population	T098	C1257890
27660323	613	630	structured search	T052	C1706202
27660323	634	657	bibliographic databases	T170	C0079198
27660323	663	670	MEDLINE	T170	C0025141
27660323	672	678	EMBASE	T170	C0079198
27660323	680	686	PubMed	T170	C1138432
27660323	688	694	CINAHL	T170	C0079198
27660323	696	712	Cochrane CENTRAL	T170	C0079198
27660323	746	774	randomised controlled trials	T062	C0206035
27660323	779	793	cohort studies	T081	C0009247
27660323	812	818	use of	T169	C1524063
27660323	819	822	TxA	T109,T121	C0040613
27660323	826	843	paediatric trauma	T037	C3714660
27660323	844	852	patients	T101	C0030705
27660323	882	886	data	T078	C1511726
27660323	906	912	search	T052	C1706202
27660323	949	957	language	T171	C0023008
27660323	961	972	publication	T057	C0034037
27660323	973	977	time	T079	C0040223
27660323	985	998	deduplication	T169	C0205245
27660323	1000	1009	citations	T170	C0552371
27660323	1046	1053	authors	T097	C3812881
27660323	1072	1081	inclusion	T080	C1512693
27660323	1104	1112	criteria	T078	C0243161
27660323	1114	1129	Data extraction	T062	C1707635
27660323	1134	1138	risk	T078	C0035647
27660323	1142	1146	bias	T078	C0242568
27660323	1147	1157	assessment	T058	C0220825
27660323	1197	1206	duplicate	T169	C0205173
27660323	1208	1229	Meta-analytic methods	T062	C0920317
27660323	1297	1304	primary	T080	C0205225
27660323	1305	1320	data collection	T062	C0010995
27660323	1333	1349	ethical approval	T080	C0205540
27660323	1386	1394	findings	T169	C2607943
27660323	1417	1429	disseminated	T082	C0205221
27660323	1440	1465	peer-reviewed publication	T073,T170	C0034036
27660323	1473	1481	relevant	T080	C2347946
27660323	1482	1501	conference meetings	T058	C0586182